Conotoxins: Review and docking studies to determine potentials of conotoxin as an anticancer drug molecule

Current Topics in Medicinal Chemistry

Volumn 12, Issue 8, 2012, Pages 845-851

  Dave, Kirtan ^a   Lahiry, Anasuya ^b  

^a SARDAR PATEL UNIVERSITY   (India)

^b Gujarat State Biotechnology Mission ^*  (India)

Author keywords

Anti cancer; Conotoxin; Docking; Drug; Potassium Channel

Indexed keywords

CONOTOXIN; KAPPA CONOTOXIN PVIIA; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ARTICLE; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; MOLECULAR DOCKING; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CONOTOXINS; CONUS SNAIL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860289962     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612800166765     Document Type: Article

References (52)

1. Prevarskaya, N.; Skryma, R.; Shuba, Y. Ion channels and the hallmarks of cancer. Trends Mol. Med., 2010, 16, 107-121.
2. Arcangeli, A.; Crociani, O.; Lastraioli, E.; Masi, A.; Pillozzi, S.; Becchetti, A. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr. Med. Chem., 2009, 16, 66-93.
3. Conti, M. Targeting ion channels for new strategies in cancer diagnosis and therapy. Curr. Clin. Pharmacol., 2007, 2, 135-144.
4. Prevarskaya, N.; Skryma, R.; Bidaux, G.; Flourakis, M.; Shuba, Y. Ion channels in death and differentiation of prostate cancer cells. Cell Death Differ., 2007, 14, 1295-1304.
5. Fiske, J. L.; Fomin, V. P.; Brown, M. L.; Duncan, R. L.; Sikes, R. A. Voltage-sensitive ion channels and cancer. Cancer Metastasis Rev., 2006, 25, 493-500.
6. Schonherr, R. Clinical relevance of ion channels for diagnosis and therapy of cancer. J. Membr. Biol., 2005, 205, 175-184.
7. Kunzelmann, K. Ion channels and cancer. J. Membr. Biol., 2005, 205, 159-173.
8. Trepel, J. B. Ion channels as molecular targets in prostate cancer. Clin. Prostate. Cancer, 2003, 2, 188-189.
9. Abdul, M.; Hoosein, N. Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett., 2002, 186, 99-105.
10. Lastraioli, E.; Guasti, L.; Crociani, O.; Polvani, S.; Hofmann, G.; Witchel, H.; Bencini, L.; Calistri, M.; Messerini, L.; Scatizzi, M.; Moretti, R.; Wanke, E.; Olivotto, M.; Mugnai, G.; Arcangeli, A. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res., 2004, 64, 606-611.
11. Becchetti, A.; Arcangeli, A. A Comment on ion channels as pharmacological targets in oncology. J. Gen. Physiol., 2008, 132, 313-314.
12. Crociani, O.; Guasti, L.; Balzi, M.; Becchetti, A.; Wanke, E.; Olivotto, M.; Wymore, R. S.; Arcangeli, A. Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J. Biol. Chem., 2003, 278, 2947-2955.
13. González-Díaz, H.; González-Díaz, Y.; Santana, L.; Ubeira, F. M.; Uriarte, E. Proteomics, networks and connectivity indices. Proteomics, 2008, 8, 750-778.
14. Ivanciuc, O. Weka machine learning for predicting the phospholipidosis inducing potential. Curr. Top. Med. Chem., 2008, 8, 1691-1709.
15. Gonzalez-Diaz, H.; Prado-Prado, F.; Ubeira, F. M. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr. Top. Med. Chem., 2008, 8, 1676-1690.
16. Duardo-Sanchez, A.; Patlewicz, G.; Lopez-Diaz, A. Current topics on software use in medicinal chemistry: intellectual property, taxes, and regulatory issues. Curr. Top. Med. Chem., 2008, 8, 1666-1675.
17. Wang, J. F.; Wei, D. Q.; Chou, K. C. Drug candidates from traditional chinese medicines. Curr. Top. Med. Chem., 2008, 8, 1656-1665.
18. Helguera, A. M.; Combes, R. D.; Gonzalez, M. P.; Cordeiro, M. N. Applications of 2D descriptors in drug design: a DRAGON tale. Curr. Top. Med. Chem., 2008, 8, 1628-1655.
19. Gonzalez, M. P.; Teran, C.; Saiz-Urra, L.; Teijeira, M. Variable selection methods in QSAR: an overview. Curr. Top. Med. Chem., 2008, 8, 1606-1627.
20. Caballero, J.; Fernandez, M. Artificial neural networks from MATLAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN): application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1). Curr. Top. Med. Chem., 2008, 8, 1580-1605.
21. Wang, J. F.; Wei, D. Q.; Chou, K. C. Pharmacogenomics and personalized use of drugs. Curr. Top. Med. Chem., 2008, 8, 1573-1579.
22. Vilar, S.; Cozza, G.; Moro, S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr. Top. Med. Chem., 2008, 8, 1555-1572.
23. Gonzalez-Diaz, H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr. Top. Med. Chem., 2008, 8, 1554.
24. Khan, M. T. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Curr. Drug Metab., 11, 285-295.
25. Mrabet, Y.; Semmar, N. Mathematical methods to analysis of topology, functional variability and evolution of metabolic systems based on different decomposition concepts. Curr. Drug Metab., 11, 315-341.
26. Martinez-Romero, M.; Vazquez-Naya, J. M.; Rabunal, J. R.; Pita-Fernandez, S.; Macenlle, R.; Castro-Alvarino, J.; Lopez-Roses, L.; Ulla, J. L.; Martinez-Calvo, A. V.; Vazquez, S.; Pereira, J.; Porto-Pazos, A. B.; Dorado, J.; Pazos, A.; Munteanu, C. R. Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network. Curr. Drug Metab., 11, 347-368.
27. Zhong, W. Z.; Zhan, J.; Kang, P.; Yamazaki, S. Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation. Curr. Drug Metab., 11, 296-306.
28. Wang, J. F.; Chou, K. C. Molecular modeling of cytochrome P450 and drug metabolism. Curr. Drug Metab., 11, 342-346.
29. Gonzalez-Diaz, H.; Duardo-Sanchez, A.; Ubeira, F. M.; Prado-Prado, F.; Perez-Montoto, L. G.; Concu, R.; Podda, G.; Shen, B. Review of March-inside & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr. Drug Metab., 11, 379-406.
30. Garcia, I.; Diop, Y. F.; Gomez, G. QSAR & complex network study of the HMGR inhibitors structural diversity. Curr. Drug Metab., 11, 307-314.
31. Chou, K. C. Graphic rule for drug metabolism systems. Curr. Drug Metab., 11, 369-378.
32. Marrero-Ponce, Y.; Casañola-Martín, G. M.; Khan, M. T. H.; Torrens, F. A. R.; Abad, C. Ligand-based computer-aided discovery of tyrosinase inhibitors. applications of the TOMOCOMD-CARDD method to the elucidation of new compounds. Curr. Pharm. Des., 2010, 16(24),2601-2624.
33. Roy, K.; Ghosh, G. Exploring QSARs with extended topochemical atom (ETA) indices for modeling chemical and drug toxicity. Curr. Pharm. Des., 2010, 16, (24), 2625-2639.
34. Munteanu, C. R.; Fernández-Blanco, E.; Seoane, J. A.; Izquierdo-Novo, P.; Rodríguez-Fernández, J. A.; Prieto-González, J. M.; Rabuñal, J. R.; Pazos, A. Drug discovery and design for complex diseases through QSAR Computational Methods. Curr. Pharm. Des., 2010, 16(24), 2640-2655.
35. Speck-Planche, A.; Scotti, M. T.; de Paulo-Emerenciano, V. Current Pharmaceutical Design of antituberculosis drugs: Future perspectives. Curr. Pharm. Des., 2010, 16 (24), 2656-2665.
36. García, I.; Fall, Y.; Gómez, G. QSAR, Docking, and CoMFA studies of GSK3 inhibitors. Curr. Pharm. Des., 2010, 16(24), 2666-2675.
37. Estrada, E.; Molina, E.; Nodarse, D.; Uriarte, E. Structural Contributions of Substrates to their Binding to P-Glycoprotein. A TOPS-MODE Approach. Curr. Pharm. Des., 2010, 16(24), 2676-2709.
38. Concu, R.; Podda, G.; Ubeira, F. M.; González-Díaz, H. Review of QSAR models for Enzyme Classes of Drug targets: Theoretical background and Applications in Parasites, Hosts, and other organisms. Curr. Pharm. Des., 2010, 16(24), 2710-2723.
39. Vázquez-Naya, J. M.; Martínez-Romero, M.; Porto-Pazos, A. B.; Novoa, F.; Valladares-Ayerbes, M.; Pereira, J.; Munteanu, C. R.; Dorado, J. Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology. Curr. Pharm. Des., 2010, 16(24), 2724-2736.
40. González-Díaz, H.; Romaris, F.; Duardo-Sanchez, A.; Pérez-Montoto, L. G.; Prado-Prado, F.; Patlewicz, G.; Ubeira, F. M. Predicting Drugs and Proteins in Parasite Infections with Topological Indices of Complex Networks: Theoretical backgrounds, Aplications, and Legal issues. Curr. Pharm. Des., 2010, 16(24), 2737-2764.
41. Garcia, E.; Scanlon, M.; Naranjo, D. A marine snail neurotoxin shares with scorpion toxins a convergent mechanism of blockade on the pore of voltage-gated K channels. J. Gene. Physiol., 1999, 114, 141-157.
42. Jacobsen, R. B.; Koch, D. E.; Lange-Malecki, B.; Stocker, M.; Verhey, J.; Van Wagoner, R. M.; Vyazovkina, A.; Olivera, B. M.; Terlau, H. Single Amino Acid Substitutions in κ-Conotoxin PVIIA Disrupt Interaction with the Shaker K+ Channel. J. Biol. Chem., 2008, 275, 24639-24644.
43. Aguilar, M. B.; Lopez-Vera, E.; Heimer de la Cotera, E. P.; Falcon, A.; Olivera, B. M.; Maillo, M. I-conotoxins in vermivorous species of the West Atlantic: peptide sr11a from Conus spurius. Peptides, 2007, 28, 18-23.
44. Azam, L.; McIntosh, J. M. Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors. Acta Pharmacol. Sin., 2009, 30, 771-783.
45. Heinemann, S. H.; Leipold, E. Conotoxins of the O-superfamily affecting voltage-gated sodium channels. Cell. Mol. Life Sci., 2007, 64, 1329-1340.
46. Jacob, R. B.; McDougal, O. M. The M-superfamily of conotoxins: a review. Cell. Mol. Life Sci., 2010, 67, 17-27.
47. Leipold, E.; DeBie, H.; Zorn, S.; Borges, A.; Olivera, B. M.; Terlau, H.; Heinemann, S. H. muO conotoxins inhibit NaV channels by interfering with their voltage sensors in domain-2. Channels (Austin), 2007, 1, 253-262.
48. Norton, R. S. Mu-conotoxins as leads in the development of new analgesics. Molecules, 2010, 15, 2825-2844.
49. Yuan, D. D.; Liu, L.; Shao, X. X.; Peng, C.; Chi, C. W.; Guo, Z. Y. New conotoxins define the novel I3-superfamily. Peptides, 2009, 30, 861-865.
50. Zugasti-Cruz, A.; Aguilar, M. B.; Falcon, A.; Olivera, B. M.; Heimer de la Cotera, E. P. Two new 4-Cys conotoxins (framework 14) of the vermivorous snail Conus austini from the Gulf of Mexico with activity in the central nervous system of mice. Peptides, 2008, 29, 179-185.
51. Torres, A. M.; Bansal, P. S.; Sunde, M.; Clarke, C. E.; Bursill, J. A.; Smith, D. J.; Bauskin, A.; Breit, S. N.; Campbell, T. J.; Alewood, P. F.; Kuchel, P. W.; Vandenberg, J. I. Structure of the HERG K+ channel S5P extracellular linker: role of an amphipathic alpha-helix in C-type inactivation. J. Biol. Chem., 2003, 278, 42136-42148.
52. Manríque, V; Galdámez, A; Veliz, B; Rovirosa, J; Díaz-Marrero, A. R; Cueto, M; Darias, J; Martínez C.; San-Martín A. N-Methyl- 1h-Indole-2-carboxamide from the marine fungus Cladosporium cladosporioides. J. Chil. Chem. Soc., 2009, 54, 314-316.